%0 Journal Article %T Melphalan dose in myeloma patients ¡Ý65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study %J - %D 2018 %R https://doi.org/10.1038/s41409-018-0379-y %X The optimal melphalan dose prior to autologous stem cell transplantation (ASCT) is not known for elderly multiple myeloma (MM) patients. We analyzed data of all MM patients ¡Ý65 years (n£¿=£¿388) enrolled in the observational Swiss Blood Stem Cell Transplantation Registry. The median age was 67 years (65¨C77). Single ASCT was performed in 344 (88.7%) patients, with 259 patients (75.3%) receiving a melphalan dose of 200£¿mg/m2 (MEL200), and 85 patients (24.7%) receiving lower doses (MELlow) (median 140£¿mg/m2, range 70£¿180£¿mg/m2). MEL200 patients were slightly younger, and had a better renal function, but did not differ with regards to ISS stage, cytogenetic risk, remission status, and KPS. Overall mortality at day 100 was 1.5% without differences between the MEL groups (p£¿=£¿0.621). Median progression-free survival (PFS) in the MEL200 and the MELlow group was 27.7 and 22.1 months, respectively (p£¿=£¿0.294). Median overall survival (OS) in the MEL200 and in MELlow group was 91.2 and 61.2 months (p£¿=£¿0.015). However, multivariate analysis showed no significant association of the melphalan dose and OS (HR 0.734; CI95% 0.264¨C2.038; p£¿=£¿0.553). In conclusion, our data reveal no significant differences in safety and PFS for elderly myeloma patients treated with MEL200 or with lower MEL doses %U https://www.nature.com/articles/s41409-018-0379-y